Treatment progress of chronic lymphocytic leukemia / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
; (12): 5-7, 2019.
Article
in Zh
| WPRIM
| ID: wpr-732675
Responsible library:
WPRO
ABSTRACT
Chronic lymphocytic leukemia (CLL) is one of the common lymphoid malignancies. Single agent ibrutinib has 74% progression-free survival (PFS) rate in RESONATE-2 trial, but ibrutinib-based therapy combined with obinutuzumab or rituximab in recent iLLUMINTE trial and ALLIANCE trail have 79% and 88% PFS rate respectively, which brings encouraging results. New inhibitors and chimeric antigen receptor T-cell (CAR-T) immunotherapy provide new treatment regimens for CLL patients who relapsed after receiving ibrutinib. The clinical trials have been done in phase Ⅰ/Ⅱ.
Full text:
1
Index:
WPRIM
Language:
Zh
Journal:
Journal of Leukemia & Lymphoma
Year:
2019
Type:
Article